SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Nifty Healthcare Index Companies

BSE Sensex 76811.77
24.01 (-0.03%)

See MoneyWorks4me's rating on Quality, Valuation, Price Trend and Overall Rating to take informed stock investing decisions. Decizen :- Q: Quality, V: Valuation, PT: Price Trend

Filter

Nifty Healthcare Index companies as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	CMP	Price Change (%)	Market Cap (Cr)	52Week High	52Week Low	ROE(%)	P/E	P/BV	EV/ EBITDA	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Cipla Ltd	Q V PT	1,439	2.07%	1,13,894 Large Cap	1,672 23 Oct, 25	1,166 02 Apr, 26	11.57	33.79	3.24	18.28	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Laurus Labs Ltd	Q V+ PT	1,728	0.80%	92,623 Mid Cap	1,734 27 Jul, 26	811 12 Aug, 25	17.86	84.70	16.43	45.46	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Glenmark Pharmaceuticals Ltd	Q V+ PT	2,202	0.34%	61,928 Mid Cap	2,471 29 Apr, 26	1,794 28 Oct, 25	15.43	45.47	5.89	12.07	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Sun Pharmaceutical Industries Ltd	Q V+ PT	1,980	0.31%	4,73,509 Large Cap	1,977 27 Jul, 26	1,547 26 Sep, 25	14.80	41.25	5.67	23.65	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Divis Laboratories Ltd	Q V+ PT	7,432	0.21%	1,96,881 Large Cap	7,455 27 Jul, 26	5,638 29 Sep, 25	15.58	76.67	11.75	48.99	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Abbott India Ltd	Q V PT	27,869	0.20%	59,102 Mid Cap	35,280 30 Jul, 25	25,164 27 Apr, 26	34.24	38.08	12.45	26.07	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Lupin Ltd	Q V PT	2,414	0.16%	1,10,189 Mid Cap	2,530 16 Jul, 26	1,839 06 Aug, 25	26.43	20.66	4.92	11.95	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Max Healthcare Institute Ltd	Q V+ PT	1,116	0.13%	1,08,476 Mid Cap	1,302 13 Aug, 25	904 07 Apr, 26	14.68	75.20	10.23	46.01	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Alkem Laboratories Ltd	Q V+ PT	5,620	0.11%	67,124 Mid Cap	5,933 13 Jan, 26	4,741 11 Aug, 25	17.86	30.72	4.80	22.28	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Apollo Hospitals Enterprise Ltd	Q V+ PT	8,852	0.10%	1,27,149 Large Cap	9,009 15 Jul, 26	6,680 28 Jan, 26	15.77	85.19	12.76	47.64	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Zydus Lifesciences Ltd	Q V PT	1,109	0.05%	1,10,523 Mid Cap	1,181 08 Jul, 26	836 02 Apr, 26	17.64	21.93	4.25	13.45	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Mankind Pharma Ltd	Q V PT	2,552	0.03%	1,05,357 Mid Cap	2,670 22 Sep, 25	1,910 23 Mar, 26	13.55	51.71	6.44	32.38	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Aurobindo Pharma Ltd	Q V+ PT	1,549	0.02%	89,115 Mid Cap	1,636 03 Jul, 26	1,017 02 Sep, 25	8.24	36.90	3.92	25.31	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Biocon Ltd	Q V PT	435	-0.14%	71,063 Mid Cap	447 16 Jul, 26	331 11 Aug, 25	0.71	1910.29	2.60	132.14	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Fortis Healthcare Ltd	Q V+ PT	940	-0.24%	71,140 Mid Cap	1,105 13 Oct, 25	767 02 Apr, 26	2.28	308.84	7.71	130.03	23.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Dr. Reddys Laboratories Ltd	Q V+ PT	1,148	-0.28%	96,063 Mid Cap	1,414 29 Jun, 26	1,080 23 Jul, 26	10.90	29.81	2.52	15.31	12.09	15.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Ipca Laboratories Ltd	Q V+ PT	1,771	-0.36%	45,090 Mid Cap	1,941 17 Jul, 26	1,253 24 Oct, 25	16.05	39.81	5.65	23.96	7.35	1.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Syngene International Ltd	Q V+ PT	412	-0.39%	16,710 Small Cap	728 30 Jul, 25	380 06 Apr, 26	8.49	54.80	3.58	18.14	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Piramal Pharma Ltd	Q V PT	191	-0.47%	25,569 Small Cap	210 29 Jul, 25	133 23 Mar, 26	6.31	36.53	3.17	19.70	10.23	-6.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Torrent Pharmaceuticals Ltd	Q V+ PT	4,985	-0.64%	1,90,832 Large Cap	5,085 16 Jul, 26	3,480 14 Oct, 25	29.04	88.21	22.69	45.79	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Nifty Healthcare Index - Today's Top Gainers

Company Name	CMP	Price Change(%)
Cipla	1,439	2.07%
Laurus Labs	1,728	0.80%
Glenmark Pharma.	2,202	0.34%
Sun Pharma. Inds.	1,979.65	0.31%
Divis Laboratories	7,432.05	0.21%

Nifty Healthcare Index - Today's Top Losers

Company Name	CMP	Price Change(%)
Torrent Pharma	4,985	-0.64%
Piramal Pharma	191.15	-0.47%
Syngene Internatl.	412.35	-0.39%
Ipca Laboratories	1,770.90	-0.36%
Dr. Reddys Labs.	1,147.70	-0.28%

News about Nifty Healthcare Index

Jul, 2026

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

Jul, 2026

Divi's Laboratories informs about earnings call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi's Laboratories has informed that it enclosed the schedule of earnings conference call for the quarter ended June 30, 2026, to be held on August 01, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Track Now:

5 Star Companies Large Cap Companies Mid Cap Companies Small Cap Companies Nifty Microcap Companies Top IT Companies Tax saver funds Analyze your Equity Funds Nifty Index Funds

All Indices

Broad Based Indices:

Nifty 50 Nifty Next 50 Nifty 100 Nifty 200 Nifty Total Market Nifty 500 Nifty Midcap 150 Nifty Midcap 50 Nifty Midcap Select Nifty Midcap 100 Nifty Smallcap 250 Nifty Smallcap 50 NIFTY Smallcap 100 Nifty Microcap 250 Nifty Largemidcap 250 Nifty500 Multicap 50:25:25

Sectoral Indices:

Nifty Auto Nifty Bank Nifty Healthcare Nifty IT Nifty Financial Services Nifty Media Nifty Metal Nifty Pharma Nifty Private Bank Nifty PSU Bank Nifty Realty Nifty Consumer Durables Nifty Oil & Gas Nifty Financial Services 25/50 Nifty Financial Services Ex Bank Nifty FMCG

Thematic Indices:

Nifty Aditya Birla Group Nifty Core Housing Nifty Commodities Nifty CPSE Nifty Financial Services Nifty Energy Nifty Housing Nifty India Consumption Nifty India Defence Nifty India Digital Nifty India Manufacturing Nifty Infrastructure Nifty Mahindra Group Nifty Midcap Liquid 15 Nifty MNC Nifty Mobility Nifty PSE Nifty Non-cyclical Consumer Nifty Services Sector Nifty Shariah 25 Nifty Tata Group Nifty Tata Group 25% Cap Nifty Transportation & Logistics Nifty100 Liquid 15 Nifty50 Shariah Nifty500 Shariah NIFTY SME EMERGE Nifty100 Esg NIFTY100 Enhanced ESG Nifty100 ESG Sector Leaders

Strategy Indices:

Nifty100 Equal Weight Nifty100 Low Volatility 30 Nifty 50 Arbitrage Nifty200 Momentum 30 NIFTY100 Alpha 30 Nifty Alpha 50 Nifty Alpha Low-volatility 30 Nifty Alpha Quality Low-volatility 30 Nifty Alpha Quality Value Low-volatility 30 Nifty Growth Sectors 15 Nifty High Beta 50 NIFTY100 Quality 30 NIFTY Midcap150 Quality 50 Nifty Quality Low Volatility 30 Nifty50 Dividend Points Nifty50 Equal Weight Nifty50 Value 20 Nifty500 Value 50 Nifty200 Quality 30

Nifty Healthcare Index FAQs

You can use different criterias to arrive at the list of best stocks in the Nifty Healthcare Index company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Healthcare Index companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,869	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,985	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,189	20.66	4.92	11.95	26.43
Alkem Laboratories Ltd. (M)	Very Good	5,620	67,124	30.72	4.80	22.28	17.86
Laurus Labs Ltd. (M)	Very Good	1,728	92,623	84.70	16.43	45.46	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,728	92,623	105
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,985	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,549	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,189	23.52
Apollo Hospitals Enterprise Ltd. (L)	Somewhat Good	8,852	1,27,149	18.40
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Max Healthcare Institute Ltd. (M)	N/A	1,116	1,08,476	75.20	10.23	46.01	27.27
Fortis Healthcare Ltd. (M)	Not Good	940	71,140	309	7.71	130	23.15
Mankind Pharma Ltd. (M)	Very Good	2,552	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Max Healthcare Institute Ltd. (M)	N/A	1,116	1,08,476	75.20	10.23	46.01	155
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,189	20.66	4.92	11.95	32.37
Apollo Hospitals Enterprise Ltd. (L)	Somewhat Good	8,852	1,27,149	85.19	12.76	47.64	29.94
Abbott India Ltd. (M)	Very Good	27,869	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,148	96,063	29.81	2.52	15.31	15.75

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Nifty Healthcare Index Companies

News about Nifty Healthcare Index

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Laurus Labs - Quaterly Results

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Divi's Laboratories informs about earnings call

Sun Pharmaceutical Industries informs about press release

Track Now:

Trending Blogs

All Indices

Nifty Healthcare Index FAQs

How to select the top Nifty Healthcare Index stocks based on RoE?

What are the best-performing stocks in the Nifty Healthcare Index index?

Which Nifty Healthcare Index stocks have the highest revenue growth in the past five years?

Which Nifty Healthcare Index stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.